Please complete Pre-test

Chapter 1 of 1



Release Date: November 29, 2021
Expiration Date: December 31, 2024

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

Join Dr. Jonas as he discusses novel uses for hypomethylating agents (HMAs) in AML and MDS. Topics include venetoclax-based regimens, novel HMA combinations, and HMAs as maintenance therapy.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurse practitioners, pharmacists and other allied healthcare professionals who provide care to patients with acute myeloid leukemia.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Utilize HMA as part of a low-intensity therapeutic strategy in those unfit for intensive chemotherapy
  • Investigate the potential role of HMAs in combination with BCL2 inhibitors and small-molecule targeted therapies
  • Explore the role of HMAs in maintenance therapy for AML
  • Incorporate novel oral HMAs into standard practice where appropriate


New Uses for Hypomethylating Agents (HMAs) – Brian A. Jonas, MD, PhD, FACP

Instructions for Participation and Credit

This activity is eligible for credit through November 29, 2022. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Brian A. Jonas, MD, PhD, FACP
Associate Professor of Medicine
Division of Hematology and Oncology
University of California, Davis
Sacramento, California

Dr. Brian Jonas received his medical degree and PhD in biochemistry and molecular biology from UC Davis School of Medicine. He completed his internship, residency, and a fellowship in hematology and oncology at Stanford University School of Medicine. He is an Associate Professor of Medicine in the Division of Hematology and Oncology at the University of California, Davis.

Dr. Jonas is a member of the American Association for Cancer Research, American College of Physicians, American Medical Association, American Physician-Scientist Association, American Society of Clinical Oncology, American Society of Hematology, Myelodysplastic Syndrome Foundation, and the Southwest Oncology Group (SWOG), among others. His clinical and research interests focus on acute myeloid leukemia, myelodysplastic syndrome, acute lymphoblastic leukemia, and other myeloid malignancies. He leads the Acute Leukemia and MDS research program and is chair of the Hematologic Malignancies Disease Team at the UC Davis Comprehensive Cancer Center. Dr. Jonas’ research focuses on developmental therapeutics and biomarker development, with an emphasis on early drug development and leukemia stem cells.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at [email protected].

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Bristol-Myers Squibb.

©2021 MediCom Worldwide, Inc., 660 Newtown Yardley Rd, Suite 203 · Newtown, PA 18940, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.50 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-21-043-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an accredited continuing education activity to disclose all financial relationships with any ineligible company. The ACCME defines “ineligible companies” as any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products by or on patients. A relevant relationship exists if a financial relationship in any amount exists between the person in control of content and an ineligible company; the financial relationship existed during the past 24 months and the content of the education is related to the products of an ineligible company with whom the person has a financial relationship. MediCom will identify mitigation strategies for all persons with relevant financial relationships who control content of the educational activity.

Faculty Disclosure

Dr. Brian Jonas has received honoraria as a consultant from AbbVie Inc.; GlycoMimetics, Inc.; Pharmacyclics, Inc.; and Treadwell Therapeutics. He has received grant support related to research activities from AbbVie; Accelerated Medical Diagnostics, LLC; AROG Pharmaceuticals, Inc.; Celgene Corporation; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd; FORMA Therapeutics, Inc.; Genentech - A Member of the Roche Group; GlycoMimetics; Hanmi Pharm. Co., Ltd; Incyte Corporation; Jazz Pharmaceuticals plc; LP Therapeutics Inc.; Pfizer Inc.; Pharmacyclics, Inc.; and Sigma-Tau Pharmaceuticals, Inc.

All of the relevant financial relationships listed for these individuals have been mitigated.

Unapproved Product Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses of products or devices.

Planning Committee

Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Lillian McVey, Medical Writer, and Andrea Mathis, Project Manager, planners for this educational activity, have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Peer Reviewer

Peer reviewer(s) for this educational activity have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.